EBMT 2022 | Advantages of using CAR-NKs for the treatment of hematological malignancies
Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, discusses the advantages of using chimeric antigen receptor-engineered natural killer cells (CAR-NKs) in the treatment of hematological malignancies. Prof. Ullrich first highlights the advantages of having numerous available sources for CAR-NK cells and their ability to be produced for both allogeneic and haploidentical cell therapies. Following this, Prof. Ullrich highlights the benefits of current and new technologies in CAR-NK production, such as ribonucleoprotein (RNP)-based electroporation and the Sleeping Beauty transposon system. To conclude, Prof. Ullrich explains the exciting future of this field, drawing focus on the increased use of non-viral transduction protocols and how these may positively impact CAR-NK clinical trials. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
